Allergy Therapeutics PLC Hardman Research: Investment driving market share
January 20 2017 - 2:15AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
20 January 2017
Hardman Research: Investment driving market share gains
Investment driving market share gains: AGY is a long-established
specialist in the prevention, diagnosis and treatment of allergies.
Pollinex Quattro continues to gain market share despite being
available in Europe only on a 'Named Patient' basis. Trials to
obtain full regulatory approval as a biological have progressed
well in the EU, and are back on-track in the US with a planned new
safety trial. AGY remains on course to have the first short-course
allergy vaccine approved in both Europe and the US. Meanwhile, an
excellent trading performance in 1H'17 shows that AGY is continuing
to gain market share from its international peers.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/20.01.17-investment-driving-market-share-gains.pdf
To contact us: Contact: Dr Martin Hall mh@hardmanandco.com
Hardman & Co Dr Dorothea Hill dmh@hardmanandco.com
11/12 Tokenhouse Dr Gregoire Pave gp@hardmanandco.com
Yard Telephone: +44 20 7929 3399
London Follow us on Twitter @HardmanandCo
EC2R 7AS
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAPFNFDEXEFF
(END) Dow Jones Newswires
January 20, 2017 02:15 ET (07:15 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024